Statistics from Altmetric.com
We read with great interest the article “Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions,” by Lux et al.1 Avastin and Lucentis have become the standard of care for choroidal neovascularisation with a better visual acuity outcome than other well-studied therapies.2 3 The use of Macugen and photodynamic therapy (PDT) is declining rapidly. The current challenge with the new anti-vascular endothelial growth factor treatment is to determine which eyes do and do not respond to …
Competing interests: None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.